A novel frameshift mutation of the ATM gene in a Chinese family with hereditary gastrointestinal tumors

References

• Armstrong SA, Schultz CW, Azimi-Sadjadi A, Brody JR, Pishvaian MJ. 2019. ATM dysfunction in pancreatic adenocarcinoma and associated therapeutic implications. Mol Cancer Ther. 18:1899–1908.
   PubMed Web of Science ®Google Scholar
• Baretić D, Pollard H, Fisher D, Johnson C, Williams R. 2017. Structures of closed and open conformations of dimeric human ATM. Sci Adv. 3:e1700933.
   PubMed Web of Science ®Google Scholar
• Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, Wiley K, Na R, Shi Z, Petkewicz J, et al. 2019. Germline mutations in ATM and BRCA1/2 Are associated with grade reclassification in Men on active surveillance for prostate cancer. Eur Urol. 75:743–749.
   PubMed Web of Science ®Google Scholar
• Economopoulou P, Dimitriadis G, Psyrri A. 2015. Beyond BRCA: new hereditary breast cancer susceptibility genes. Cancer Treat Rev. 41:1–8.
   PubMed Web of Science ®Google Scholar
• Frimer M, Levano K, Rodriguez-Gabin A. 2016. Germline mutations of the DNA repair pathways in uterine serous carcinoma. Gynecol Oncol. 141:101–107.
   PubMed Web of Science ®Google Scholar
• Grant R, Selander I, Connor A. 2015. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 148:556–564.
   PubMed Web of Science ®Google Scholar
• Hall MJ, Bernhisel R, Hughes E, Larson K, Rosenthal ET, Singh NA, Lancaster JM, Kurian AW. 2021. Germline pathogenic variants in the ataxia telangiectasia mutated (ATM) gene are associated with high and moderate risks for multiple cancers. Cancer Prev Res (Phila). 14:433–440.
   PubMed Web of Science ®Google Scholar
• Han M, Ma L, Qu Y, Tang Y. 2017. Decreased expression of the ATM gene linked to poor prognosis for gastric cancer of different nationalities in Xinjiang. Pathol Res Pract. 213:908–914.
   PubMed Web of Science ®Google Scholar
• Helgason H, Rafnar T, Olafsdottir HS, Jonasson JG, Sigurdsson A, Stacey SN, Jonasdottir A, Tryggvadottir L, Alexiusdottir K, Haraldsson A, et al. 2015. Loss-of-function variants in ATM confer risk of gastric cancer. Nat Genet. 47:906–910.
   PubMed Web of Science ®Google Scholar
• Huang D-S, Tao H-Q, He X-J, Long M, Yu S, Xia Y-J, Wei Z, Xiong Z, Jones S, He Y, et al. 2015. Prevalence of deleterious ATM germline mutations in gastric cancer patients. Oncotarget. 6:40953–40958.
   PubMedGoogle Scholar
• Kastrinos F, Samadder NJ, Burt RW. 2020. Use of family history and genetic testing to determine risk of colorectal cancer. Gastroenterology. 158:389–403.
   PubMed Web of Science ®Google Scholar
• Li J, Jing R, Wei H. 2019. Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer. Int J Cancer. 144:281–289.
   PubMed Web of Science ®Google Scholar
• Lin P, Yeh Y, Wu P, Hsu K, Chang J, Shen M. 2019. Germline susceptibility variants impact clinical outcome and therapeutic strategies for stage III colorectal cancer. Sci Rep. 9:1–10.
   PubMed Web of Science ®Google Scholar
• Liu R, Tang J, Ding C, Liang W, Zhang L, Chen T, Xiong Y, Dai X, Li W, Xu Y, et al. 2017. The depletion of ATM inhibits colon cancer proliferation and migration via B56γ2-mediated Chk1/p53/CD44 cascades. Cancer Lett. 390:48–57.
   PubMed Web of Science ®Google Scholar
• Ma H, Brosens LAA, Offerhaus GJA, Giardiello FM, de Leng WWJ, Montgomery EA. 2018. Pathology and genetics of hereditary colorectal cancer. Pathology. 50:49–59.
   PubMed Web of Science ®Google Scholar
• Mahon SM. 2016. Management of individuals with a mutation in the ataxia telangiectasia mutated gene. Oncol Nurs Forum. 43:114–117.
   PubMed Web of Science ®Google Scholar
• McGillivray E, Farma J, Savage M, Hall MJ, Luo B, Jain R. 2021. Pathologic complete response in patient With ATM mutation after neoadjuvant FOLFOXIRI plus panitumumab therapy for locally advanced colon cancer: A case report. Clin Colorectal Cancer. 20:e96–e99.
   PubMed Web of Science ®Google Scholar
• Michailidi C, Theocharis S, Tsourouflis G, Pletsa V, Kouraklis G, Patsouris E, Papavassiliou AG, Troungos C. 2015. Expression and promoter methylation status of hMLH1, MGMT, APC, and CDH1 genes in patients with colon adenocarcinoma. Exp Biol Med (Maywood). 240:1599–1605.
   PubMed Web of Science ®Google Scholar
• Neeb A, Herranz N, Arce-Gallego S, Miranda S, Buroni L, Yuan W, Athie A, Casals T, Carmichael J, Rodrigues DN, et al. 2021. Advanced prostate cancer with ATM loss: PARP and ATR inhibitors. Eur Urol. 79:200–211.
   PubMedGoogle Scholar
• Oue N, Sentani K, Sakamoto N, Uraoka N, Yasui W. 2019. Molecular carcinogenesis of gastric cancer: Lauren classification, mucin phenotype expression, and cancer stem cells. Int J Clin Oncol. 24:771–778.
   PubMed Web of Science ®Google Scholar
• Pearlman R, Frankel W, Swanson B, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow P. 2017. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol. 3:464–471.
   PubMed Web of Science ®Google Scholar
• Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody W, Hegde M, Lyon E, Spector E. 2015. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 17:405–423.
   PubMed Web of Science ®Google Scholar
• Santos JC, Gambeloni RZ, Roque AT, Oeck S, Ribeiro ML. 2018. Epigenetic mechanisms of ATM activation after Helicobacter pylori infection. Am J Pathol. 188:329–335.
   PubMed Web of Science ®Google Scholar
• Sato Y, Hirakawa M, Ohnuma H, Takahashi M, Okamoto T, Okamoto K, Miyamoto H, Muguruma N, Furuhata T, Takemasa I, et al. 2017. A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study. Cancer Chemother Pharmacol. 80:1133–1139.
   PubMed Web of Science ®Google Scholar
• Swift M, Morrell D, Cromartie E, Chamberlin AR, Skolnick MH, Bishop DT. 1986. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet. 39:573–583.
   PubMed Web of Science ®Google Scholar
• Swift M, Reitnauer PJ, Morrell D, Chase CL. 1987. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med. 316:1289–1294.
   PubMed Web of Science ®Google Scholar
• Tao Y, Mei Y, Ying R, Chen S, Wei Z. 2020. The ATM rs189037 G > A polymorphism is associated with the risk and prognosis of gastric cancer in Chinese individuals: A case-control study. Gene. 741:144578.
   PubMed Web of Science ®Google Scholar
• van Os NJH, Roeleveld N, Weemaes CMR, Jongmans MCJ, Janssens GO, Taylor AMR, Hoogerbrugge N, Willemsen MAAP. 2016. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet. 90:105–117.
   PubMed Web of Science ®Google Scholar
• Wahl R. 2020. The interaction of genomics, molecular imaging, and therapy in gastrointestinal tumors. Semin Nucl Med. 50:471–483.
   PubMed Web of Science ®Google Scholar
• Weigelt B, Bi R, Kumar R, Blecua P, Mandelker D, Geyer F, Pareja F, James P, Investigators k, Couch F. 2018. The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers. JNCI: J National Cancer Institute. 110:1030–1034.
   PubMedGoogle Scholar
• Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, et al. 2022. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 135:584–590.
   PubMed Web of Science ®Google Scholar
• Zhang H, Feng M, Feng Y, Bu Z, Li Z, Jia S, Ji J. 2018. Germline mutations in hereditary diffuse gastric cancer. Chin J Cancer Res. 30:122–130.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhao Z, Zhang Y, Bao C, Cui L, Cai S, Bai Y, Shen L XZ. 2020. Pathogenic germline mutations in Chinese patients with gastric cancer identified by next-generation sequencing 2020. Oncology. 98:583–588.
   PubMed Web of Science ®Google Scholar